Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial

Francesco Travaglino, Veronica Russo, Benedetta De Berardinis, Filippo Numeroso, Pamela Catania, Gianfranco Cervellin, Stefano Geniere Nigra, Francesco Geraci, Maria Antonietta Bressan, Stefania Guerrini, Mario Cavazza, Christian Folli, Valter Monzani, Stefania Battista, Giulio Mengozzi, Paola Noto, Giuseppe Carpinteri, Andrea Semplicini, Federica Stella, Stella IngrassiaPaolo Moscatelli, Patrizia Giuntini, Gerardo Salerno, Patrizia Cardelli, Salvatore Di Somma

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Introduction Mid-regional pro-atrial natriuretic peptide (MR-proANP), procalcitonin (PCT), and mid-regional pro-adrenomedullin (MR-proADM) demonstrated usefulness for management of emergency department patients with dyspnea. Methods To evaluate in patients with dyspnea, the prognostic value for 30 and 90 days mortality and readmission of PCT, MR-proADM, and MR-proANP, a multicenter prospective study was performed evaluating biomarkers at admission, 24 and 72 hours after admission. Based on final diagnosis, patients were divided into acute heart failure (AHF), primary lung diseases, or both (AHF + NO AHF). Results Five hundred one patients were enrolled. Procalcitonin and MR-proADM values at admission and at 72 hours were significantly (P

Original languageEnglish
Pages (from-to)334-341
Number of pages8
JournalAmerican Journal of Emergency Medicine
Volume32
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Adrenomedullin
Calcitonin
Dyspnea
Heart Failure
Mortality
Atrial Natriuretic Factor
Lung Diseases
Multicenter Studies
Hospital Emergency Service
Biomarkers
Prospective Studies

ASJC Scopus subject areas

  • Emergency Medicine

Cite this

Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial. / Travaglino, Francesco; Russo, Veronica; De Berardinis, Benedetta; Numeroso, Filippo; Catania, Pamela; Cervellin, Gianfranco; Nigra, Stefano Geniere; Geraci, Francesco; Bressan, Maria Antonietta; Guerrini, Stefania; Cavazza, Mario; Folli, Christian; Monzani, Valter; Battista, Stefania; Mengozzi, Giulio; Noto, Paola; Carpinteri, Giuseppe; Semplicini, Andrea; Stella, Federica; Ingrassia, Stella; Moscatelli, Paolo; Giuntini, Patrizia; Salerno, Gerardo; Cardelli, Patrizia; Di Somma, Salvatore.

In: American Journal of Emergency Medicine, Vol. 32, No. 4, 2014, p. 334-341.

Research output: Contribution to journalArticle

Travaglino, F, Russo, V, De Berardinis, B, Numeroso, F, Catania, P, Cervellin, G, Nigra, SG, Geraci, F, Bressan, MA, Guerrini, S, Cavazza, M, Folli, C, Monzani, V, Battista, S, Mengozzi, G, Noto, P, Carpinteri, G, Semplicini, A, Stella, F, Ingrassia, S, Moscatelli, P, Giuntini, P, Salerno, G, Cardelli, P & Di Somma, S 2014, 'Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial', American Journal of Emergency Medicine, vol. 32, no. 4, pp. 334-341. https://doi.org/10.1016/j.ajem.2013.12.045
Travaglino, Francesco ; Russo, Veronica ; De Berardinis, Benedetta ; Numeroso, Filippo ; Catania, Pamela ; Cervellin, Gianfranco ; Nigra, Stefano Geniere ; Geraci, Francesco ; Bressan, Maria Antonietta ; Guerrini, Stefania ; Cavazza, Mario ; Folli, Christian ; Monzani, Valter ; Battista, Stefania ; Mengozzi, Giulio ; Noto, Paola ; Carpinteri, Giuseppe ; Semplicini, Andrea ; Stella, Federica ; Ingrassia, Stella ; Moscatelli, Paolo ; Giuntini, Patrizia ; Salerno, Gerardo ; Cardelli, Patrizia ; Di Somma, Salvatore. / Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial. In: American Journal of Emergency Medicine. 2014 ; Vol. 32, No. 4. pp. 334-341.
@article{880586944ed44faf8fe339b058b54456,
title = "Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial",
abstract = "Introduction Mid-regional pro-atrial natriuretic peptide (MR-proANP), procalcitonin (PCT), and mid-regional pro-adrenomedullin (MR-proADM) demonstrated usefulness for management of emergency department patients with dyspnea. Methods To evaluate in patients with dyspnea, the prognostic value for 30 and 90 days mortality and readmission of PCT, MR-proADM, and MR-proANP, a multicenter prospective study was performed evaluating biomarkers at admission, 24 and 72 hours after admission. Based on final diagnosis, patients were divided into acute heart failure (AHF), primary lung diseases, or both (AHF + NO AHF). Results Five hundred one patients were enrolled. Procalcitonin and MR-proADM values at admission and at 72 hours were significantly (P",
author = "Francesco Travaglino and Veronica Russo and {De Berardinis}, Benedetta and Filippo Numeroso and Pamela Catania and Gianfranco Cervellin and Nigra, {Stefano Geniere} and Francesco Geraci and Bressan, {Maria Antonietta} and Stefania Guerrini and Mario Cavazza and Christian Folli and Valter Monzani and Stefania Battista and Giulio Mengozzi and Paola Noto and Giuseppe Carpinteri and Andrea Semplicini and Federica Stella and Stella Ingrassia and Paolo Moscatelli and Patrizia Giuntini and Gerardo Salerno and Patrizia Cardelli and {Di Somma}, Salvatore",
year = "2014",
doi = "10.1016/j.ajem.2013.12.045",
language = "English",
volume = "32",
pages = "334--341",
journal = "American Journal of Emergency Medicine",
issn = "0735-6757",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial

AU - Travaglino, Francesco

AU - Russo, Veronica

AU - De Berardinis, Benedetta

AU - Numeroso, Filippo

AU - Catania, Pamela

AU - Cervellin, Gianfranco

AU - Nigra, Stefano Geniere

AU - Geraci, Francesco

AU - Bressan, Maria Antonietta

AU - Guerrini, Stefania

AU - Cavazza, Mario

AU - Folli, Christian

AU - Monzani, Valter

AU - Battista, Stefania

AU - Mengozzi, Giulio

AU - Noto, Paola

AU - Carpinteri, Giuseppe

AU - Semplicini, Andrea

AU - Stella, Federica

AU - Ingrassia, Stella

AU - Moscatelli, Paolo

AU - Giuntini, Patrizia

AU - Salerno, Gerardo

AU - Cardelli, Patrizia

AU - Di Somma, Salvatore

PY - 2014

Y1 - 2014

N2 - Introduction Mid-regional pro-atrial natriuretic peptide (MR-proANP), procalcitonin (PCT), and mid-regional pro-adrenomedullin (MR-proADM) demonstrated usefulness for management of emergency department patients with dyspnea. Methods To evaluate in patients with dyspnea, the prognostic value for 30 and 90 days mortality and readmission of PCT, MR-proADM, and MR-proANP, a multicenter prospective study was performed evaluating biomarkers at admission, 24 and 72 hours after admission. Based on final diagnosis, patients were divided into acute heart failure (AHF), primary lung diseases, or both (AHF + NO AHF). Results Five hundred one patients were enrolled. Procalcitonin and MR-proADM values at admission and at 72 hours were significantly (P

AB - Introduction Mid-regional pro-atrial natriuretic peptide (MR-proANP), procalcitonin (PCT), and mid-regional pro-adrenomedullin (MR-proADM) demonstrated usefulness for management of emergency department patients with dyspnea. Methods To evaluate in patients with dyspnea, the prognostic value for 30 and 90 days mortality and readmission of PCT, MR-proADM, and MR-proANP, a multicenter prospective study was performed evaluating biomarkers at admission, 24 and 72 hours after admission. Based on final diagnosis, patients were divided into acute heart failure (AHF), primary lung diseases, or both (AHF + NO AHF). Results Five hundred one patients were enrolled. Procalcitonin and MR-proADM values at admission and at 72 hours were significantly (P

UR - http://www.scopus.com/inward/record.url?scp=84897456489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897456489&partnerID=8YFLogxK

U2 - 10.1016/j.ajem.2013.12.045

DO - 10.1016/j.ajem.2013.12.045

M3 - Article

C2 - 24559907

AN - SCOPUS:84897456489

VL - 32

SP - 334

EP - 341

JO - American Journal of Emergency Medicine

JF - American Journal of Emergency Medicine

SN - 0735-6757

IS - 4

ER -